The first two vaccines for COVID-19 from Pfizer Inc. and Moderna, Inc. could be approved for emergency use by the US Food and Drug Administration later in December, marking the first mass vaccination effort in the US in decades. Director of adult immunization and senior advisor on policy advocacy and communications at the Johns Hopkins Bloomberg School of Public Health's International Vaccine Access Center Lois Privor-Dumm has been focusing on that task and the realities for a large-scale COVID-19 vaccination plan for the US.
Privor-Dumm talked to Scrip about reasons for optimism, the challenges of vaccinating a broad and diverse population, and what drug...
